Skip to content
Triangle logo TriangleGet started
← Study library

NCT01302366 · REGISTRY CONDITION SEARCH

A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2015-02-12

This study proposes to determine the clinical activity of this agent in patients with asymptomatic multiple myeloma. It is believed that TBL12 will help delay the onset of active multiple myeloma, with very few-if any- side effects.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Duration of Response (All Treated Patients)

→

outcome · POSTED

Percentage of Patients Who Have Responded to TBL12

→

outcome · POSTED

Duration of Response (Excluding Patient Choice and Non-compliance)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Diagnosis of multiple myeloma based on standard criteria as follows: Major Criteria * Plasmacytomas on tissue biopsy * Bone marrow plasmacytosis (\> 30% plasma cells) * Monoclonal immunoglobulin (Ig) spike on serum electrophoresis (IgG \> 3.5 g/dL or IgA \> 2.0 g/dL); kappa or lambda light chain excretion \> 1 g/day on 24 hour urine protein electrophoresis Minor Criteria * Bone marrow plasmacytosis (10 to 30% plasma cells) * Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria * Normal IgM \< 50 mg/dL, IgA \< 100 mg/dL, or IgG \< 600 mg/dL Any of the following sets of criteria will confirm the diagnosis of Multiple Myeloma: * Any two of the major criteria * Major criterion 1 plus minor criterion b, c * Major criterion 3 plus minor criterion a or c * Minor criteria a, b and c * Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of ≥ 1 g/dL and/or urine monoclonal immunoglobulin spike of ≥ 200 mg/24 hours. * Non-secretors must have measurable protein by Freelite or measurable disease such as plasmacytoma to be eligible. * Has asymptomatic disease, i.e., does not have hypercalcemia, renal insufficiency, anemia or bone lesions. * Karnofsky performance status ≥ 80 (See Appendix B) * Is infertile (i.e. surgically sterile or 12 months post-menopausal) or is practicing an adequate form of contraception, as judged by the investigator (i.e., birth control pills, double barrier method, abstinence, etc.) * Age 18 years or older * Has given voluntary written informed consent, prior to any study-related procedure not part of normal medical care, with the understanding that the patient may withdraw consent at any time without prejudice to future medical care. Exclusion Criteria: * Prior treatment for myeloma (symptomatic or asymptomatic). * POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes) * Plasma cell leukemia * Patients with a history of thyroid problems. * Receiving steroids \> the equivalent of 10 mg prednisone daily for other medical conditions, e.g., asthma, systemic lupus erythematosis, rheumatoid arthritis * Infection not controlled by antibiotics * Human Immunodeficiency Virus (HIV) infection. Patients should provide consent for HIV testing according to the institution's standard practice * Known active hepatitis B or C * New York Hospital Association (NYHA) Class III or IV heart failure or EKG evidence of acute ischemic disease * Second malignancy requiring treatment in last 3 years * Other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol * Positive pregnancy test in women of childbearing potential
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    TBL12 is administered orally at a dose of 2 units (of 20 mL each) twice a day, in 4-week cycles, until disease progression or there is sign of disease progression.
    intervention Names
    1. Drug: TBL12
    label
    Sea cucumber extract
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Sea cucumber extract
    name
    TBL12
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
20
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Response \[complete response (CR), partial response (PR), and stable disease (SD)\] was assessed after approximately 2 months, 6 months and then every 4 months, until progression of disease. Response and progression of disease evaluation is based on the criteria reported by Blade, et al. (1998).
    measure
    Duration of Response (All Treated Patients)
    time Frame
    up to 3 years
  2. description
    Response \[complete response (CR), partial response (PR), and stable disease (SD)\] was assessed after approximately 2 months, 6 months and then every 4 months, until progression of disease. Response and progression of disease evaluation is based on the criteria reported by Blade, et al. (1998).
    measure
    Duration of Response (Excluding Patient Choice and Non-compliance)
    time Frame
    up to 3 years
secondary Outcomes
  1. description
    Response to TBL12 is defined as SD or better after 2 cycles of TBL12. The evaluation of SD, PR, or CR is based on the report by Blade et al. (1998)
    measure
    Percentage of Patients Who Have Responded to TBL12
    time Frame
    2 months
Full study description
brief Summary
This study proposes to determine the clinical activity of this agent in patients with asymptomatic multiple myeloma. It is believed that TBL12 will help delay the onset of active multiple myeloma, with very few-if any- side effects.
detailed Description
Multiple myeloma is a cancer that evolves from a state known as Monoclonal Gammopathy of Undetermined Significance (MGUS), defined by parameters of M spike and bone marrow. After evolution to myeloma, patients may be asymptomatic, that is, without any endorgan disease of hypercalcemia, renal insufficiency, anemia or bone lesions. In asymptomatic myeloma (ASxM), there is no standard therapy. Thalidomide has been tried in patients with ASxM but with significant toxicity. The patients with ASxM are evaluable in terms of paraprotein measurements. TBL12 sea cucumber extract has been shown to have a number of antitumor properties preclinically, including antiangiogenesis and direct tumor cytotoxicity. TBL12 has been used by a number of patients as a food supplement without any toxicity detected. The investigators thus propose to determine the clinical activity of this agent in patients with ASxM. Patients will be given TBL12 at the dose of 2 units of 20 mL each twice per day daily until disease progression and the effects on the paraprotein noted. Clinical effects seen will be correlated with any in vitro changes in angiogenesis in patient bone marrow samples. The results of this trial may form the basis for the use of this nontoxic agent in patients with the prodrome of or with other early cancers.
Source references
references
  1. citation
    Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998 Sep;102(5):1115-23. doi: 10.1046/j.1365-2141.1998.00930.x. No abstract available.
    pmid
    9753033
    type
    BACKGROUND
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-cca195514736a9f525be
      requested nct id
      NCT01302366
      primary nct id
      NCT01302366
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      a635388cd879bf505821c8e30943649bd7dd94ade85688bb33c9124a447fd369
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-cca195514736a9f525be
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01302366
      occurrences
      1. context exact
        NCT01302366
        end
        11
        exact text
        NCT01302366
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/996/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      799ca6196360c1c4d9ed2adcd91c6d8814b78b3b88afcc7dbc7d0be4d55d0481

    Preserved source evidence · Not medical advice